Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal) (TA1118)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 January 2026
NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal) (TA745)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 November 2021
Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 8 February 2021Published: 24 February 2010
Mifamurtide for the treatment of osteosarcoma (TA235)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 October 2011
Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (TA86)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 November 2010Published: 27 October 2004